SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Minimal Clip Art Collage. Pop Vector Design Composition with bright bold geometric shapes, halftone objects for ad, animation etc
Approvals
SpringWorks Wins FDA Nod for Neurofibromatosis Drug, Tees Up Challenge to AstraZeneca
The approval comes days after Germany’s Merck KGaA confirmed it was in advanced talks to acquire SpringWorks.
February 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Leadership
Vir Leans Into Immunology Roots After Flamed-Out COVID Fame
Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer stepped in as CEO to answer a critical question: What’s next?
February 12, 2025
 · 
5 min read
 · 
Annalee Armstrong
Incyte's logo on its building in Delaware
Collaboration
Incyte Backs Out of Immuno-Oncology Pact With Agenus
The partnership dates back to 2015, when Incyte paid $60 million upfront for access to four checkpoint programs, including TIM-3, LAG-3, OX40 and GITR.
February 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Gilead's headquarters in Silicon Valley
Infectious disease
Anticipating Approval, Gilead Gears Up for Mid-Year Launch for Lenacapavir PrEP
Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.
February 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Vector illustration of Retro styled Abstract Businessman caught up in a bureaucratic Spiders Web. Hi-res Jpeg, PNG and PDF files included.
Government
Trump’s Whiplash Policies Keep Pharmas on Their Toes
As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.
February 12, 2025
 · 
4 min read
 · 
Annalee Armstrong
Podcast
New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron sues Sanofi over an alleged failure to provide adequate information about Dupixent sales.
February 12, 2025
 · 
1 min read
 · 
Heather McKenzie
Limited resources, profit distribution, resource sharing concept. Three hands with forks and one pie chart. Minimalist collage
GLP-1
Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.
February 12, 2025
 · 
2 min read
 · 
Annalee Armstrong
Illustration of a group of businessmen white-collar workers dismissed
Layoffs
Inventiva to Halve Its Workforce, Shift Focus to MASH Candidate
French biotech Inventiva’s layoffs and pipeline shift are expected to help keep the company operational into the second half of 2026.
February 11, 2025
 · 
1 min read
 · 
Angela Gabriel
New York City, NY, USA - August 22, 2022: Pfizer world headquarters in New York City, USA. Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation.
Prostate cancer
Leaked Conference Article Shows Pfizer’s Positive Phase I Prostate Cancer Data
A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating castration-resistant prostate cancer.
February 11, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS